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Summary 
The last decade was stimulating with the introduction of new molecular 
techniques to be applied in pathology laboratories. Accordingly, cytology was 
also benefited with the innovations emerged from this new era. Molecular 
cytopathology (MCP) can be defined as molecular studies applied on all types 
of cytological specimens, namely gynaecology cytology, exfoliative non-gyn 
cytology and fine needle aspirates. The development of a huge amount of new 
ancillary techniques has paralleled the emergence of clinical cytology as a 
major diagnostic speciality. Clinical applications of these techniques have been 
growing in the last decade. The widespread acceptance of liquid-based systems 
in gynaecological cytology is a paramount episode which re-draws the relation 
between cells and molecules. The stretched use of approaches, morphology 
and molecular biology, in HPV-induced lesions settings, e.g., revealed a 
potential to optimize, in one single brushed sample, diagnosis and research. 
Cytology samples from serous effusions, pulmonary tree, bladder urine, and 
aspirations, among others, are now likely to be studied by different molecular 
techniques for helping in diagnosis, prognosis, or even to assess therapeutic 
targets. In this review, we highlight the main results already published 
concerning the application of molecular techniques in different fields of 
cytopathology and discuss their application. 
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TAKE HOME MESSAGES –  
• Since molecular biology results are meaningful only when interpreted 
with proper morphologic correlation, it is important to standardize 
molecular techniques at pre-analytical and analytical levels.
 
• In the three fields of cytology there are applications of molecular 
techniques that are now part of the routine assessment, such as HPV 
testing on cervicovaginal specimens, FISH in effusions, urine, or 
aspirates; for diagnosis or to assess therapeutic targets. 
• As more molecular targets for therapy are identified, cytopathologists will 
be increasingly called upon to help identify patients who are suitable 
candidates for therapeutic agents that target such molecules. 
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Introduction 
Molecular technology applied in pathology diagnostic field is undoubtedly 
reshaping the practice of cytopathology worldwide. A multi-institutional inquiry 
recently invocated an interesting discussion concerning the introduction of these 
methodologies to optimize cytology procedures and solving old quandaries1. 
Particular attention has been dedicated to the real utility of these new 
techniques and the feasibility to introduce them in cytology laboratories. The 
conclusions are quite exciting because most of the cytopathologists now 
recognize the importance of the molecular techniques as adjuncts to 
morphology for diagnosis. At this moment the great challenge is deciding when 
to adopt a new molecular test and who should perform and interpret it. Since 
molecular biology results are meaningful only when interpreted with proper 
morphologic correlation, it is important to standardize molecular techniques at 
pre-analytical and analytical levels. Cytology as a medical specialty is also call 
for changes. These include stronger working relationships between 
cytopathologists and bench scientists, between cytopathologists in academia 
and those in community hospitals and between cytopathologists and other 
physicians; there are also needed for new training programs that provide 
opportunity to understand and accelerate as we learn how better to use the 
tools we have and to incorporate new technologies into these processes.  
 There are many advantages to use cytological material over histology to 
perform molecular biology studies. DNA and RNA are better preserved on 
cytology specimens and as is easy to obtain fresh whole cells, the assessment 
can be immediate done. The possibility to perform genomic and proteomic 
studies 2,3 in small quantity of material, as for example obtained by fine-needle 
aspiration can minimize invasive procedures, allowing the tumour monitorization 
with repeating tests. Additionally, cytological samples preserved in liquid-based 
preservative mediums offer molecular material of high quality in comparison to 
those obtained from paraffin-embedded tissues. Nonogaki et al 4, showed that 
detection of beta-Globin, an internal control universally used to PCR assay, was 
detected in 100% of cervical cytological specimens against 66.7% of the 
corresponding biopsies. Indeed, there are some limitations to be taken in 
account when tissue samples are used for molecular investigation. The main 
limitations are related to the formalin fixative process and the paraffin inclusion.  
Impaired DNA and RNA preservation have been observed and this condition 
seriously affects its identification with the PCR assay. Likewise, the 
environmental conditions of storage and processing of the tissues are barely 
controllable, and the reproducibility of molecular assay can be seriously 
restricted 4. The use of proteomics technologies have been progressively 
considered as a tool to monitoring protein expression in tumour cells. This 
approach augments the possibilities to early detect cancer recurrence and also 
improves cancer diagnosis recognizing proteins released by the cancer cells. 
Importantly, these technologies allow the use of different fresh biological 
samples, including tissue and cytological specimens, such as aspirates, body 
fluids, urine and bronchial speciments3, 5.  
 The goal of this review is to present and discuss the magnitude of most 
available technologies and demystified the use of molecular techniques on the 
three fields of cytology: exfoliative gynaecological cytology, exfoliative 
nongynaecologic cytology and fine needle aspiration cytology (FNAC). 






The cytology of lower gynaecological tract, the notorious “Pap Test”, is certainly 
one of the most favoured fields of cytopathology following the introduction of 
new technologies. After several years demonstrating problems of poor rates of 
both sensitivity and unsatisfactory samples, the Pap Test was improved with the 
introduction of liquid-based cytology (LBC) preparations and the potential use of 
residual material to molecular investigation. 
 
Importance of liquid medium 
In spite of some contentious reports, LBC reduced significantly the number of 
unsatisfactory samples5-7. The sensitivity for high grade lesions of LBC in 
general population is quite similar to the Pap smear, but in high risk population, 
LBC performance is significantly superior8.  Additionally, LBC systems have 
introduced qualified mediums which allows not only the cellular integrity for 
morphological studies, but also preserve proteins and DNA/RNA contents 9-11. 
The maintenance of molecular characteristics of cells in LBC medium can also 
provide opportunity to study several genes involved in transformed exfoliated 
cervical cells 12,13. This is vital because allow to study molecules in different 
conditions and for different purposes. Importantly, long term storage of LBC 
medium is also another essential property because permit to study samples 
years after its collection, with minor DNA/RNA damage.  Actually, it was 
observed that HPV identification by Hybrid Capture II (HC2) procedure, e.g., 
was not affected by storage14.    
 
 
The importance of detecting high risk HPV 
Presently, liquid medium are closely associated with daily routine of Pap 
Test, contributing with new paradigms of cervical cancer prevention. Primarily 
thought to be used in combination with cervical cytology, HPV testing is now 
seriously considered as first option for screen cervical HPV-induced lesions 
because the robustness of some recent data from large screening studies. 
Table 1 show brief current advantages to include a molecular test such as 
hybrid capture (HC2) as an option to screen general population. It should be 
considered that the differences of HC2 performance compared with cytology 
(Pap Test) could not only improve diagnoses but also be more cost-effective. 
For many authors cervical cytology is now indicated as a reflex test to 
determine which HPV-positive women require additional follow-up or 
colposcopy15. HPV testing for primary screen option offers the advantage to 
create infection registries that can link test results from the same women over 
time, thus allowing an efficient and low-cost strategy to monitor long-term 
protection among vaccinated women16. This is remarkable because in the era of 
HPV-vaccine is important not only to discriminate HPV-negative from positive 
women but also to map the HPV subtypes in order to establish robust data 
about epidemiologic distribution of HPV worldwide17.  Additionally, HPV test is 
feasible to be introduced in population out of the Public Health services through 
self-sampling collection. Recent data have been demonstrated that this tool is a 
very suitable alternative method for studies on HPV transmission and vaccine 
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trials18. In terms of laboratorial facilities, protocols for probe production and 
applied approaches to pathogen genotyping are now accessible through the 
use of highly discriminating probes, which could potentially be applied to the 
detection and characterization of HPV19.   
Table 1 show a comparison between a molecular method (Hybrid 
Capture) and morphology (cytology) to perform cervical cancer screening in 
large populations. Table 2, demonstrate a comparison of HPV detection among 
the several molecular techniques now available. 
 
Markers for HPV integration and progression 
There are many other potential useful options to be considerate for 
molecular marker-based assays, which can be summarised in the follow arms: 
chromosomal abnormalities, DNA adduct formation, cell cycle check points, 
oncogene expression/function, tumour suppressor gene expression, apoptotic 
markers, epigenetic regulation such as methylation and metabolic markers20. 
This is attractive because residual LBC material can be used for a number of 
purposes. One of the most accepted in cytology is the immunocytochemistry 
reaction which is interesting to investigate protein expression complementary to 
molecular analysis.  The p16 accumulation is observed in intraepithelial lesions 
and cancer, and its expression is consequence of high risk HPV E7 activity. 
Overexpression of p16 is related with proliferation and in reality, the positive 
immunocytochemical reaction for cell cycle marker Ki-67 increased almost in 
parallel with the increasing grade of p16-positivity in cervical lesions18. 
Overexpression of p16(INK4A) is believed to be a diagnostic marker for cervical 
squamous and also glandular neoplastic lesions in LBC and a useful marker of 
cervical dyskaryosis21,22. The use of fragile histidine triad (FHIT) as a marker for 
cervical lesions is still contentious but its inactivation seems to be a later event, 
probably related with evolution from intraepithelial lesions to invasive 
carcinoma23. FHIT expression seems to occur in inverse way of the p16 
because their DNA loss was commonly found in invasive carcinomas of the 
cervix24. For this reason, FHIT immunohistochemical expression is believed to 
be useful for prognoses purposes in cervical lesions when used in combination 
with p1623.  
HPV-transformed cells present alterations associated to cell adhesion 
properties, cytoskeleton and cell surface structures which lead to a cellular 
morphology alteration. The expression of members of cadherins super family, 
adhesion-associated proteins, may be altered in many tumours, and its 
recognition is valuable to diagnoses and prognoses intention. P-cadherin 
expression, e.g., was demonstrated to be highly specific marker to identify 
cervical malignancies 25.  
 Epigenetic mechanism of gene inactivation in cervical cancer has been 
recently reported. DNA methylation is an early alteration in carcinogenesis and 
is frequently found in precursor cancer lesions. Cervical exfoliated cells 
preserved in liquid medium are convenient to be used for aberrant promoter 
methylation analysis 26. The frequency of hypermethylation is supposed to 
increase with increasing severity of cervical lesion. Frequency of 
hypermethylated genes such DAPK1, RARB, or TWIST1 is highly found (close 
to 80%) in invasive squamous cells carcinoma, moderately in high grade 
lesions, but very low in low grade lesions (5%). The most encouraged 
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observation is the absence of hypermethylation in normal cervix, which may be 
considerable as valuable marker to cervical cancer investigation26.  
Other different studies to investigate genomic alterations in cervical 
cancer are available as well, using metaphase comparative genomic 
hybridization (mCGH) and microsatellite marker analysis for the detection of 
loss of heterozygosity (LOH). At present, high throughput methods such as 
array comparative genomic hybridization (array CGH), single nucleotide 
polymorphism array (SNP array) and gene expression arrays are available to 
study genome-wide alterations. Together, these platforms permit the recognition 
of genomic variations at high resolution and, more than that, investigation of an 
association between copy number changes and expression, that can be 
confirmed by fluorescent in situ hybridization (FISH) 27. Most genetic 
imbalances have been associated with decreased survival such as LOH of 18q 
or with the transition from severe dysplasia to invasive carcinoma such as gain 
of 3q. The progression of cervical intraepithelial neoplasia (CIN) 2/3 to cervical 
carcinoma includes integration of human papillomavirus (HPV) into the host 
genome, genomic instability, and an increase in chromosome 3q copy number. 
In particular, the gene coding for the RNA component of telomerase (TERC) at 
3q26 has been implicated as a possible candidate gene which can be evaluated 
with the use of FISH technology  24.  
Recently, FISH and chromogenic in situ hybridization (CISH) assays 
were demonstrated practical to be performed in both cytological and tissue 
samples. This type of methodology is not so complicate to standardize in 
cytology laboratories, allow concomitant morphological analysis and have 
multiple uses (see in non-gynaecological cytology). Until now, in cervical 
samples the study of 3q amplification is the most common 24  .  
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In effusions, fluorescence in situ hybridization (FISH), comparative genomic 
hybridisation (CGH) and other molecular biology techniques have been 
successfully used to characterize malignant neoplastic cells and therefore, 
improve diagnostic accuracy.  There are two clinical situations in which 
these techniques are useful: - for searching metastatic cells and for 
characterising of mesotheliomas.28. Until now, the wide-accepted ancillary 
method for serous effusion cytology is immunocytochemistry. Several 
antibodies has importantly improved the cytological diagnoses on serous 
effusions 29,30, but for maximising its efficiency, the use of a panel of markers 
is recommended because of the lack of specificity of many of antibodies 31. 
Some examples are TTF-1, CK7 and CK20 (adenocarcinoma of the lung vs. 
metastasis of extrapulmonary adenocarcinoma), CDX2 (colorectal 
adenocarcinoma), BerEP-4 and calretinin (rare carcinoma cells in pleural 
effusions), among others 1,31, However, the variable mixture of tumor cells 
and normal cells, the presence of rare atypical cells still are a challenge for 
diagnosis using morphology and immunocytochemistry. In some situations, 
molecular analysis can be helpful on effusions.  The detection of allelic loss 
in 16q22.1, including the locus of E-cadherin, in pleural effusions from breast 
cancer patients have showed that CDH1 gene can recognize tumour cells in 
pleural effusions when morphologic analysis is difficult32. Similarly, LOH 
evaluated by polymerase chain reaction assay was able to identify 
metastases in 36% of suspected cases where morphology only did not allow 
the diagnosis of malignancy.33.  
 
Lymphoma involving serous membranes  
 
One of the most complex evaluations in serous effusion is the 
categorization of lymphoid-like cells in samples suspected of lymphomas. As 
anticipated, the differential diagnosis could include reactive lymphocytosis, early 
involvement by lymph-proliferative disease, small round-cell tumours, and 
presence of look-alike of Reed-Sternberg cells34. Immunocytochemistry (ICC) is 
helpful for these circumstances but have also some limitations regarding 
neoplastic cells phenotyping 35. Flow cytometry (FCM) and ICC are both 
complementary and competitive. The preference to use one of them largely 
depends on experience with the technique, laboratory resources and expertise 
in the techniques since there are limitations of each technique34. The most 
important advantage of FCM is the multiparameter evaluation of single cells and 
the ability to work with very small samples. The recent availability of antibodies 
against the variable region of the TCR beta (V beta) chain allows determination 
of T-cell clonality by FCM which is not currently possible for IHC. The majority of 
the antibodies used for lymphoma characterization are generally available for 
both FCM and IHC, but some of them work better for FCM, such as antibodies 
to immunoglobulin κ and λ light chains, and some, such as cyclin D1 antibody, 
used for mantle cell lymphoma, works well with IHC 36. Table 3 based on 
Kaleem (2006) review36, summarize the main comparisons between ICC and 
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FCM and highlight the potential usefulness of cytological samples from serous 
effusions to precisely categorize the lymph-proliferative lesions.  
In spite of the advantages of FCM, besides immunophenotyping, current 
molecular techniques are decisive in subtyping lymphomas, such as T-cell 
lymphoblastic lymphoma (that more frequently invade the serous membrane), 
follicular centre cell lymphoma, Burkitt-type lymphoma, marginal zone 
lymphoma, MALT lymphoma, and anaplastic large-cell lymphoma, among 
others. Individually, most of the known ancillary techniques have limitations; 
thereby, the use of multiple parameters is thought to overcome this barrier36. 
The use of PCR to diagnose T cell receptor genes in low-grade peripheral T cell 
lymphomas may be occasionally required; however, the vast majority of 
lymphomas are successfully immunophenotyped and assigned clonality by 
FCM or immunocytochemistry. The use of ZAP 70 by flow cytometry correlates 
with unmutated IgVH genes and more rapid disease progression in CLL/SLL, 
and if the assay is performed appropriately, may be substituted for PCR-based 
analysis of immunoglobulin genes.1 
 
Molecular analysis of effusions 
 
Although ancillary molecular methods, including FISH, CISH and LOH, have 
become part of the diagnostic armamentarium of the diagnostic pathology 
laboratory, thorough morphological analysis coupled with detailed clinical-
pathological information is still pivotal for diagnosis-making. Moreover, a 
combination of molecular techniques can increase the accuracy of detecting 
malignant cells in dubious cases 2. Summarising, most of the important results 
can be achieved with cytogenetics (karyotype) evaluation where numerical and 
structural alterations are important parameters to discriminate cancer from non-
cancerous condition. Mesotheliomas, for example, harbour recurrent 
abnormalities on chromosome 6, such as loss of its long arm (6q -). At variance, 
adenocarcinomas in general and more specifically pulmonary adenocarcinomas 
show frequent alterations on chromosome 8, such as gains or inversions inv 
(8q). Numerical and structural alterations in chromosomes 1, 3, 6, 7, 8, 9, 11, 12 
and 17 also have been described with frequency in metastatic effusions from 
breast and ovarian cancer. Coupling conventional cytology to cytogenetics 
increases diagnostic sensitivity to up to 85.3% 2. In situ hybridization (ISH) is an 
important option to assist the analysis of serous effusion. Both, fluorescent 
(FISH) and chromogenic (CISH) in situ hybridization have been used to identify 
alterations in chromosomal sequences from certain tumours, in order to 
optimise the diagnosis of metastasis. FISH analysis with probes for 
chromosomes 7, 8, 11, 12, 17, and 18 in primary and metastatic breast 
carcinomas showed the same pattern of aneuploidy demonstrating the role of 
this technique in identifying individual aneusomic cells in suspicious samples 2. 
Fiegl et al.37 reported a statistically significant improvement of the cytological 
diagnostic accuracy using FISH analysis in effusions from breast cancer, lung 
cancer, pancreatic cancer, and in effusions from the entire group of 
gynaecological and gastrointestinal carcinomas. One of the promising methods 
for cytology as a whole is the comparative genomic hybridization (CGH) 
analysis which permits an outlining of DNA sequences and copy number 
alteration: losses, gains and amplification of genes are promptly identified. CGH 
analysis may provide information on the site of the primary tumours and also 
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distinguish cytogenetic alterations affecting oncogenes and tumour suppressor 
genes involved in neoplastic progression and metastasis38. An improved high 
resolution CGH method (array-based CGH) has been developed and already 
represents one of the most powerful techniques to recognise genetic 
alterations. DNA is hybridised in a glass slide chip with cDNA, bacterial artificial 
chromosome (BAC) or oligonucleotides DNA allowing evaluating the 
quantitative changes in the whole genome2.  Nagel et al 38 addressed the 
potential use of CGH as a diagnostic adjunct for cytopathology practice in 
serous effusions. As immunohistochemical markers are not infallible for 
distinguishing mesotheliomas from metastatic carcinomas, we have begun a 
comprehensive analysis of primary breast carcinomas, ovary carcinomas and 
mesotheliomas by means of aCGH, in order to identify a molecular genetic 
signature that would allow differentiating these two tumour types. Although 
preliminary, these results are quite promising and may eventually help 
cytopathologists differentiating mesotheliomas from other metastatic 
malignancies2. Another useful application of CGH is to establish the relationship 
between a primary tumour and its metastatic deposits. Unlike immunoprofile, 
which can dramatically change from primaries to metastases, the DNA profiles 
are more stable. Even in those cases with pronounced genetic instability, 
genomic changes that are pivotal for tumour cell growth and survival are 
reported to be maintained all across tumour progression. Therefore, CGH 
and/or aCGH could be used to define whether a poorly 
differentiated/undifferentiated neoplastic deposit came from a known primary 
tumour or is a second primary. This was recently demonstrated in lung cancer 
by Yen et al 39. In addition, we can envisage in the near future that CGH/aCGH 
method can at least be used for defining genetic regions that are preferentially 
gained or lost in mesotheliomas when compared to other tumour types that 
frequently metastasise to the serosal membranes, such as lung, breast, ovary 
and gastric cancers. By defining these regions, less complex methods, such as 
fluorescent and/or chromogenic in situ hybridisation or LOH, could be used for 
increasing the diagnostic accuracy. 
The other advance that may play an important role in overcoming the diagnostic 
dilemma benign/reactive or malignant is the telomerase assay. Telomerase is a 
ribonucleoprotein complex that synthesizes telomeric repeats onto 
chromosomal ends during cell divisions, preventing incomplete chromosomal 
replication, nuclease degradation, and end—to-end chromosomal fusions. It is 
usually inactivated in most of adult somatic cells, which lead to cell senescence 
due to progressive chromosomal degradation. However, in a large subset of 
human cancers, telomerase is reactivated during neoplastic progression. 
Telomeric repeat amplification protocol (TRAP) assay has been applied to 
cytology with interesting results, mainly to help in the interpretation of atypical 
cells in breast FNA samples, as well as in effusion cytology 2. So far, several 
studies have reported high sensitivity and specificity for telomerase activity as 
detected by TRAP in malignant cytological samples. Examples of the impact of 
telomerase activity analysis on effusions are on record, suggesting an increase 
in the diagnostic accuracy. Whilst sensitive and specific, telomerase activity is 
not as reliable as morphology. The false positive rates of TRAT assay range 
from 15 to 56% 2.  Recently, Shu et al.40 described an in situ evaluation protocol 
for telomerase activity in 103 pleural effusions showing when combined with 
cytology, sensitivity and specificity of 90% and 95%, respectively. These 
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findings support that telomerase in situ assays may play a role in the evaluation 
of difficult cytological specimens, increasing the accuracy of the diagnosis, 
since TA is reported to be more frequently activated in malignant cells.  
 MN/CA9 is a cancer-related gene, frequently activated in human 
carcinomas its evaluation by RT-PCR assay is now an enthusiastically believed 
as a promising marker for routine practice 41. In a recent study, MN/CA9 gene 
expression was detected in 53/59 (89.8%) of pleural effusions from cancer 
patients Importantly, MN/CA9 was positive in 13/18 (72.2%) of cytologically 
negative effusions of cancer patients and was detected in only 1/12 (8.3%) 
effusion from the control patients (p < 0.01) The sensitivity and specificity of 
MN/CA9 gene expression were, respectively, 89.8% and 91.7%. Although these 
results are very promising, further studies in large series needed to be done to 
confirm the utility of this marker. 
The number of new molecules is constantly increasing, and it is 
reasonable to use a panel of molecules to explore in more detail all the 
possibilities within the effusion sample42.  The RT-PCR is suitable for this 
purpose and the combination of some markers was demonstrated to be highly 
specific to identify malignant cells. However, the commonly used ICC marker 
such as carcinoembryonic antigen, epithelial cell adhesion molecule, E-
cadherin, mammaglobin, mucin 1 and its isoforms MUC1/REP, MUC1/Y, and 
MUC1/Z, calretinin, and Wilms' tumour 1 can precisely diagnose malignancy in 
several conditions. Depending on the marker specificity, some of them are also 
capable to identify some tumours; mammaglobin, e.g., is mainly expressed in 
effusions from breast carcinoma reaching almost 100% of specificity43.  
 
 
Markers of therapeutic response in effusions 
Recently, several studies in the field of cytology effusions have been 
done concerning not only diagnosis, but also prognosis and therapeutic 
response. NAC-1, a member of the bric-a-brac tram track broad 
complex/poxvirus and zinc domain family, is over-expressed in ovarian serous 
carcinoma.  NAC-1 protein expression was found more frequent in recurrent 
than primary tumours44 and the nuclear NAC-1 expression intensity is 
significantly higher in specimens obtained after the administration of 
chemotherapy been correlated with shorter progression-free survival. Moreover, 
NAC-1 expression is higher in ovarian carcinoma cells in effusions compared 
with their solid tumour counterparts. NAC-1 is believed to be up-regulated in 
tumour cells after chemotherapy, suggesting a role for this protein in tumour 
progression and in the development of chemotherapy resistance in ovarian 
cancer44. 
Immunoblotting method can be also adequately performed in serous 
effusion examination for the identification of inhibitor-of-apoptosis proteins 
(IAP)45. These proteins are related to survival and chemoresistance. Three out 
the eight known IAPs were lately investigated in mesotheliomas using 
immunoblotting and IHC: X-linked IAP (XIAP), survivin, and livin45. Interestingly, 
XIAP and survivin, but not livin, are frequently expressed in malignant 
mesotheliomas. Furthermore, nuclear expression of survivin is reduced in 
effusions as compared with solid lesions concomitantly with reduced 
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proliferation (assessed with Ki-67 score). XIAP was demonstrated, as well, to 
be up-regulated in mesothelioma effusions suggesting a pro-survival role in 
malignant mesothelioma cells45.  
 
 
Urine and multitargeted fluorescence in situ hybridisation  
 
 The cytological investigation of urine sample is very useful not only for 
diagnostic purpose but also to monitoring patients. Voided cells can be easily 
obtained and isolated from urine and analysed by a multitarget FISH technique 
using hybridization probes to chromosomes 3, 7, 9p21 and 17. The multitarget 
FISH has a well-recognised and important role in the management of bladder 
cancer1,,46-49. This technique is standardized now and it is easily applicable to 
routine material.  Currently FISH is used in conjunction with conventional 
cytology and is available to clinical use. The UroVysion® product (UroVysion, 
Vysis/Abbott, Downers Grove, IL)  is common used in different laboratories and. 
three of the four FISH probes reveal duplications of chromosomes 3, 7 and 17, 
and the fourth probe (LSI 9p21-SpectrumGold) by its absence indicates loss of 
band 9p21. These findings in exfoliated urine cells are associated with 
transitional cell carcinoma and dysplasia, but not in reactive processes or 
polyoma virus infection 1. Additionally, FISH method can identify recurrence 
earlier than the other methods.  
 
Bronchial specimens and multicolour fluorescence in situ hybridization  
 
The also called interphase multicolour fluorescence in situ hybridization (IM-
FISH) is indeed a promising tool for improving cancer diagnosis as a whole, 
because it can directly visualize multiple changes in chromosomes and gene 
copy number49. However, multiple FISH has a low sensitivity in detecting cancer 
cells because presently, few targets can be detected simultaneously by current 
commercially available IM-FISH protocols49. To overcome this constraint, 
specific genomic probes for the genes related to lung cancer were recently 
developed. Multitarget FISH containing locus specific probes to chromosomes 6 
and to the 5p15, 8q24 (c-myc gene) and 7p12 (EGFR gene) have been used to 
detect cancer cells in bronchial brushings and washings. The results showed 
that FISH is significantly more sensitive than conventional cytology for detecting 
lung cancer in bronchoscopically obtained bronchial brushing specimens and 
FISH detected tumours at earlier stages and detected a higher proportion of 
peripheral tumours 50. However, additional studies are needed to determine if 
the higher sensitivity of FISH has the potential to improve patient survival. 
Conversely, no significant differences were found in copy number gain between 
high-risk individuals for lung cancer development and healthy never-smokers. 
The gains in chromosome 6 (CEP6), 5p15, 7p12 (EGFR), and 8q24 (C-MYC), 
were not associated with smoking or asbestos exposure, therefore a sensitive 
method is still needed for the follow-up of populations at high risk of contracting 
lung cancer51. In a technical point of view, bronchial cytological specimens can 
be straightforwardly used for FISH preparation from ethanol spray-fixed smears. 
No additional slide preparation is required prior to FISH hybridisation.  
The use of large combinations of probes through the multiplex FISH is 
improving the diagnostic capacity on cytologic material. Moreover, better probes 
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to detect specific translocations will be extremely useful in the characterization 
of soft tissue tumours and malignant lymphomas in cytologic material. New 
genetic information are coming from the microarray technology and specific 
probes can be generated and used to obtain diagnostic, prognostic and 
predictive information on routine material. 
 
FINE NEEDLE ASPIRATION CYTOLOGY 
 
Fine needle aspiration (FNA) cytology has proven its value as a minimally 
invasive, easy, accurate and reliable technique for the diagnosis of several 
types of tumours. Moreover, in the last 15 years, FNA has also been used for 
the assessment of prognostic and predictive factors.  
 Interphase cytogenetics, such as FISH or CISH and PCR-based assays 
can be used in routine FNA material, for diagnostic or prognostic purposes. 
Sarcomas and haematological tumours are two major groups where molecular 
techniques are applied on FNA for diagnosis. Immunophenotyping of 
lymphomas using samples obtained through FNA has been successfully 
achieved using flow cytometry and immunocytochemistry on cytospin or even in 
previously Papanicolaou-stained slides52. Specific gene rearrangements and 
chromosomal translocations such as those involving c-myc in Burkitt’s 
lymphoma t(8;14): MYC-IgG, or ALK in anaplastic large cell lymphoma 
t(2;5)(p23;q35), or cyclin D1 in mantle cell lymphoma t(11;14)(q13;q32) among 
others, can be easily detected by means of FISH on Giemsa and Papanicolaou-
stained slides and fusion gene products can be detected in FNA samples 
through RT-PCR with specific primers52. Moreover, monoclonal rearrangements 
of the immunoglobulin heavy chain gene or T-cell receptor can be identified by 
PCR in FNA samples. Molecular techniques, such as FISH, RT-PCR and 
Southern blot technique have also successfully been applied to soft tissue 
tumours sampling by FNA, for the identification of chromosomal translocations, 
fusion gene products and gene amplification, respectively. We have previously 
demonstrated that DNA can be successfully obtained and amplified from 
archival/diagnostic cytological preparations regardless of the fixation (ethanol or 
air-dry) and staining methods53.  
 
Molecular cytology and sarcomas FNA 
 
New FISH probes designed for specific chromosomal translocations are 
now commercially available. The cytological diagnosis of soft tissue tumours 
may eventually become even more accurate, because this technique can be 
prospectively applied to conventional cytological preparations. In the diagnostic 
setting of soft tissue tumours, the use of FISH to detected the presence of 
“break apart” translocation of t(11;22)(q24;q12) to diagnose Ewing´s 
sarcoma/PNET is one of the most common use of molecular techniques for the 
differential diagnosis of small round blue cell tumours54. The synovial sarcoma 
translocation t(X;18) (q11;q11) is also very useful to diagnose this tumour in 
cases of atypical localization and morphology. Other rare sarcomas can be 
detected and diagnosed on cytological material with the demonstration of 
specific translocations, such as: alveolar rhabdomyosarcoma t (2;13) or t (1;13); 
myxoid/round cell liposarcoma t (12;16); extraskeletal myxoid chondrosarcoma t 
(9;22), among others 1, 55  
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Molecular cytology and thyroid FNA 
 
Fine needle aspiration cytology of thyroid nodules is largely admired in 
pathology routine as safe and efficient methodological option to accurately 
diagnosed thyroid nodules 56. However, inconclusive cytological features related 
to the follicular lesions are far to be solved by morphology alone and 
immunocytochemical available markers. Evidently, molecular analysis to rule 
out these constraints are welcomed, e.g. in papillary thyroid carcinoma (PTC), 
genetic events involve RET and TRK rearrangements, and BRAF and RAS 
mutations, although RAS mutations are uncommon in follicular neoplasias, 
except in the follicular variant of PTC57. These genetic alterations, which are 
rarely overlapped in the same tumour, result in signalling abnormalities in the 
mitogen activated protein kinase pathway. Alternatively, genetic alterations in 
follicular carcinomas include PAX8-PPAR gama translocations and RAS 
mutations while mutations of CTNNB1 and p53 have been implicated in the 
development and progression of poorly differentiated and undifferentiated 
(anaplastic) thyroid carcinomas57. Additionally, germline mutations of RET are 
responsible for the development of heritable forms of medullary thyroid 
carcinoma (MTC) while somatic mutations of this oncogene are found in a 
significant proportion of sporadic MTCs57.  
 Although most of the molecular alterations are well-known in thyroid 
tumours, the study of these alterations on FNA samples are still not so useful to 
solve the major problems in the field.  RET/PTC rearrangements and BRAF 
mutations can be detected in thyroid FNA but they were not present in all PTCs 
and can help only in cases of PTCs that simulate follicular tumours on cytology 
58,59
.  
Figure 1 exemplifies the use of PPAR gamma gene probe to identified 
follicular thyroid carcinoma using FISH methodology. The gene is labelled by 
two colours (split probe), normal gene is yellow (overlapping red and green 
parts). Translocation results in split of the gene and the split of the colours: 
there is one green and one red spot indicated that the part of PPAR gamma 
was translocated to another partner chromosome. PAX8-PPAR-γ 
rearrangements (as the result of a 2;3 translocation) have been recurrently 
detected in follicular carcinomas and follicular variant of papillary carcinoma (but 
not in conventional PTC). The consequence of such translocation, t(2;3)(q12-
13;p24-25), is fusion of the DNA binding domains of the thyroid transcription 
factor PAX8 to domains A-F of the PPAR-γ1. The product of the fusion gene 
blocks the action of PPAR-γ1, an effect that might inhibit cell differentiation and 
stimulate cell growth. Initially it was claimed that the PAX8-PPAR-γ translocation 
was exclusively detected in FTC and thus could be considered as sign of 
malignancy. This concept was disproved in several studies that showed the 
presence of the translocation in a number of follicular adenomas. Oncocytic 
follicular tumours, including both adenomas and carcinomas, are negative. 
These findings underscore the fact that PAX8-PPAR-γ rearrangements cannot 
be used to distinguish benign and malignant follicular cell tumours 60. 
Actually, gene selection and development of diagnostic and prognostic 
algorithms have been reported61.  An algorithm based on the expression levels 
of five genes (TERT, TFF3, PPARgamma, CITED1, and EGR2) could 
effectively predict high-risk disease with high specificity. TERT and TFF3 
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expression, e.g., discriminate adenomas from carcinomas61. Indeed, the 
analysis of atypical adenomas (AFTA) and minimally invasive follicular 
carcinomas (MI-FTC), showed that 16 out of 17 AFTAs were classified as 
benign, while MI-FTCs tend to be classified as malignant61. Remarkably, these 
findings can support the development of consistent preoperative diagnostic and 
prognostic tests that can guide the therapeutic approach of follicular thyroid 
neoplasms with indeterminate cytology.  
 
Molecular cytology and paediatric tumours 
 
  In paediatric tumours, as mentioned before, molecular techniques (FISH 
or RT-PCR) have been applied  in the differential diagnosis of small round blue 
cell tumours, showing the translocations associated to Ewings´s sarcoma/PNET 
t(11;22)(q24;q12) 54 or, for example, associated to desmoplastic small round 
cell tumor t(11;22)(p13;q12) reciprocal translocation. However, our group have 
more than ten years of experience studying N-myc amplification and 1q 
deletions in FNA from neuroblastomas to assess prognosis and to drive the 
clinical approach62. The interpretation of these results associated with the FCM 
anaysis of the tumour cells, allow us based only in cytological material, to 
separate two groups: one with good prognosis (N-myc negative and aneuploid) 
and other with worse prognosis and poor therapeutic response (N-myc positive 
and diploid). Initially studied by southern-blot, the N-myc assessment was 
replaced by FISH technique with the great advantage of concomitant 
morphological evaluation. Figure 2 document a smear from FNA of a case of 
neuroblastoma with MYC amplification.  
 
Molecular cytology and therapeutic targets  
 
 Now and in the future, cytopathologists will be expected to include 
specific prognostic and predictive information in their reports, as well as to order 
ancillary tests and to contribute in clinical trials with their expertise63, 64. Since 
the last decade, there have been an increasing number of new drugs which 
indications depends upon a pathological report. Although lymphomas, 
leukaemia and gastrointestinal stromal tumours (GISTs) are the most striking 
examples, in breast cancer this practice is also solid and there is accumulating 
experience with the hormone receptors and more recently with HER2 (erbB2).  
The use of Trastuzumab, a humanised monoclonal antibody that acts on the 
HER2 receptor, had improved the survival of the patients with HER2 
amplification65. The clinical use of trastuzumab (Herceptin) requires evaluation 
of HER2 amplification on tumours from every potentially eligible patient. Novel 
therapeutics, such as Lapatinib, an oral tyrosine kinase inhibitor, which blocks 
both the epidermal growth factor receptor and HER2 receptor, has been also 
recently approved by the US-FDA66. FISH is currently regarded as the gold 
standard method for detecting HER-2 amplification. The main difficulty for 
adopting FISH in a clinical setting is the need for additional equipment for 
analysis, such as fluorescence microscopy and multiband fluorescence filters. 
Recently, novel technology to detect DNA probes has been developed. 
Chromogenic in situ hybridization (CISH) uses a simple immunocytochemistry-
like peroxidase reaction, and the results can be assessed using a normal light 
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microscope. The assessment is fast, with good morphologic control, and the 
slides can be stored for long periods without loss of signal. CISH is a reliable 
test to assess HER2 gene copy number67. A very high level of concordance 
between CISH and FISH has been reported. In a recent study, the rate of 
concordance ranged from 93% in equivocal immunohistochemistry samples to 
98% in HER2 immunohistochemistry-positive cases and 97% in HER2 
immunohistochemistry-negative cases, with an overall concordance rate 
between CISH and FISH higher than 95%68. The limited number of 
commercially available gene probes has hindered the use of CISH. However, a 
new protocol to generate probes for CISH was recently described allowing the 
construction of probes mapping to any gene of interest to be applied to paraffin-




 . What is the role for HER2 assessment in FNA material? 
In metastatic breast cancer, Trastuzumab is used as first-line therapy after 
previous chemotherapy failure. In spite of good concordance between HER2 
status in primary tumours and lymph node metastasis, in distant metastases 
this concordance diminishes with time. So, the HER2 evaluation should be 
preferentially done in the metastatic tumour. Performing HER2 ICC studies on 
FNA material remains problematic, because HER2 scoring is not validated in 
this material. However, HER2 assessment using FISH or CISH is now possible 
and useful in FNA with excellent correlation with the histologic specimens 70 
(Figure 3). The recent approval for Herceptin in adjuvant therapy can expand 
the use of ISH in aspirates obtained from the primary tumor. 
In lung cancer, the management of non-small-cell lung cancer (NSCLC) has 
progressively changed since the introduction of the epidermal growth factor 
receptor (EGFR) TK selective inhibitors, which offers an interesting new 
opportunity for treatment. Numerous studies have been carried out to identify 
patients that could better benefit from these agents. From all characteristics and 
clinical-pathological features, molecular finding of EGFR gene somatic mutation 
emerged as one of the most potentially useful prognostic and predictive factors 
in advanced NSCLC. Recently, it was demonstrated that genomic DNA 
extracted from image-guided FNA and ⁄ or cell blocks of effusion fluid are 
sufficient for the detection of somatic EGFR mutations using nested PCR 
technique 71,72. Patients with advanced NSCLC treated by gefitinib and bearing 
EGFR mutations have significantly better response and progression-free 
survival 71 Amplification of the EGFR gene is also associated with response to 
therapy in some cases of lung cancer. These results can be useful in the setting 
of triple-negative breast cancer cases that do not have a specific therapeutic 
target EGFR amplification was detected by CISH in 30% of our cases of 
metaplastic breast carcinomas (MBCs) 73. Given that these tumours are 
resistant to conventional chemo-therapy and hormone therapy regimens, our 
findings indicate that studies are warranted to explore EGFRTK-inhibitors as 
potential therapeutic agents for MBCs harbouring amplifications of EGFR. 
Recently, our group demonstrated the feasibility of performing ICC and 
molecular analysis of c-kit and PDGFRA genes in formalin-fixed and paraffin-
embedded cell blocks obtained by endoscopic ultrasound-guided FNA from 
GISTs74. This procedure allows a more precise diagnosis and therapeutic 
decision in the routine management of patients with GISTs. Figure 4 illustrate 
an example of GIST mutation detected on cytological material.  
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Anticipating the future 
 It is very difficult to predict the progress that should be anticipated over 
the next 10 or 50 years, because cancer is such a complex problem, with 
hundreds of forms and diverse means of controlling it. However, with the 
continued aging of the population the absolute number of cancer diagnoses will 
very likely rise substantially in the coming decades. So, for the foreseeable 
future, we will need better ways to diagnose and treat cancers. In terms of 
therapy, from a practical standpoint for the cytopathologist, it will be mandatory 
to have tumour cells available from patients participating in clinical trials in order 
to study the molecular features that correlate with sensitivity or resistance to the 
cancer drug targets. The availability of tissues or cells from the patients may 
allow retrospectively identification of a molecular profile or surrogate marker 
characteristic of responding tumours, even when the demonstration of activity is 
limited to a small group of patients. In turn, this profile or marker could be used 
prospectively for patient enrolment into subsequent studies with selected 
patients. At the time of tumour progression, one could also consider 
assessment of newly acquired genetic alterations to decide on the next line of 
therapy.  
 Fine needle aspiration cytology offers a suitable alternative to biopsy in a 
variety of clinical settings, in which it may be useful to obtain material to study 
diagnostic, prognostic and predictive markers. The progress of “specific” 
therapies based on antibody response will certainly obligate the cytologists to 
actively participate in the make decision setting for patients therapeutic options. 
The rapport with clinicians will be more and more interactive and both 
professionals should be familiarised with molecular signalling pathways. The 
cytological changes of tumour cells should be faced as a preliminary approach 
of complex, but not mystic, accessible world of molecules. 
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LEGEND FOR FIGURES 
 
Figure 1. FISH with PPAR-gamma gene probe in a case of follicular thyroid 
carcinoma. The gene is labelled by two colours (split probe), normal gene is 
yellow (overlapping red and green parts). Translocation results in split of the 
gene and the split of the colours: there is one green and one red spot indicated 
that the part of PPARgamma was translocated to another partner chromosome. 
 
Figure 2. FISH with MYCN gene (red) probe and chromosome 2 centromere 
probe (green) used as a control in neuroblastoma. In a) MYCN gain (1 
supplementary copy per cell) is seen in the middle cell of the smear. B) showed 
a case with high level of amplification. 
 
Figure 3: FISH with HER2 gene (red) and chromosome 17 centromere (green) 
in an aspirate of breast cancer. In a) is demonstrated a case of polysomy of 
chromosome 17 and in b) a real HER2 amplification. 
 
Figure 4: A fine needle aspiration of GIST showing a smear stained by 
Papanicoloau technique (a). DNA was extracted from the cells and a mutation 
on exon 11 of c-Kit is demonstrated by sequencing. Arrow indicates substitution 
of a thymine by a cytosine (L576P) (b). 
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Table 1 : Comparison between a molecular method (Hybrid Capture) and morphology (cytology) to perform cervical cancer 
screening in large populations. 
 
Methodological option for 
primary screening 
Hybrid Capture 2 PapTest 
Tests per day Model 1: 384 tests day 
Model 2: 800 tests day 
Number of professionals needed: 01 
 
50 slides/ observer recommended 
For 800 samples, e.g. are needed 16 cytotechnologist  
Time to training One week Variable: one to two years 
Sensitivity ≥90% ≤60% 
Specificity High for HSIL but limited for LSIL Usually high 
Predictive negative value ≥95% ≤ 50% 
Predictive positive value Largely depends on the prevalence of the 
lesions 
Largely depends on the prevalence of the lesions 
Intervals of tests 5 years One year 
Quality Control  Included in the test Limited efficiency and high costs involved 
Reproducibility Data similar elsewhere Highly variable 
Additional tests Residual medium allow to perform cytology, 
DNA, RNA and immunocytochemistry 
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Varies Varies Varies 
Analytical 
sensitivty  
25 to 75 fg 63 to 94 fg 
 
0.1 to 100 fg 0.5 to 10 fg 0.1 to 10 fg 900-3000 
copies per cell 






13 3 39 20 43 37 Isolated types Isolated types Isolated types 
FDA approval Yes No No No No No No No No 
Commercially 
available Kit  
Yes Yes Yes No No Yes No No No 
Level of cross 
contamination 
















No No Yes Yes Yes Yes No No  
Yes 
Sensitivity High High High High High High Low Low Low 
Specificity High High High High High High Low Low Low 
Lab Working  Easy Easy Average Average Average Average to 
Complex 
Complex Complex Complex 
Potential for 
Automation  











Table 3 Comparison of flow-cytometry  and immunocytochemistry performance to study limphoproliferative diseases 
Information Flow Cytometry Immunocytochemistry 
Determination of B-cell clonality by analysis of immunoglobulin κ 
and λ light chains 
FCM performs better than IHC - 
Evaluation of co-expression profiling of antigens on the same cells, 
such as co-expression of CD5 and CD23, aberrant loss of antigens, 
and simultaneous evaluations of cytoplasmic and surface antigens 
FCM performs better than IHC - 
Evaluation of nuclear antigens such as cyclin D1 and TdT - IHC performs better than FCM 
Lymph node FNA FCM is often diagnostic and more 
informative than IHC  
Informative 
Diagnosis of central nervous system lymphoma in the spinal fluid in 
patients with acquired immune deficiency syndrome 
FCM is often diagnostic and more 
informative than IHC  
Informative 
Pleural, peritoneal, and pericardial lymphocytic effusions FCM is often diagnostic and more 
informative than IHC  
Informative 
Orbital lymphoid proliferations and intraocular fluid analysis FCM is often diagnostic and more 
informative than IHC  
Informative 
Adapted from Kaleem Z. Arch. Pathol. Lab. Med. 2006;130:1850-8 
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